LLY

807.09

-0.02%↓

UNH

508.19

-1.68%↓

NVO

136

+0.24%↑

JNJ

147.03

-1.72%↓

MRK

129.56

-1.17%↓

LLY

807.09

-0.02%↓

UNH

508.19

-1.68%↓

NVO

136

+0.24%↑

JNJ

147.03

-1.72%↓

MRK

129.56

-1.17%↓

LLY

807.09

-0.02%↓

UNH

508.19

-1.68%↓

NVO

136

+0.24%↑

JNJ

147.03

-1.72%↓

MRK

129.56

-1.17%↓

LLY

807.09

-0.02%↓

UNH

508.19

-1.68%↓

NVO

136

+0.24%↑

JNJ

147.03

-1.72%↓

MRK

129.56

-1.17%↓

LLY

807.09

-0.02%↓

UNH

508.19

-1.68%↓

NVO

136

+0.24%↑

JNJ

147.03

-1.72%↓

MRK

129.56

-1.17%↓

Search

Ardelyx Inc

Open

Sector Healthcare

6.96 -6.58

Overview

Share price change

24h

Current

Min

6.9

Max

7.47

Key metrics

By Trading Economics

Income

24M

6.6M

Sales

-22M

34M

EPS

-0.12

Profit margin

11.755

Employees

267

EBITDA

24M

7.7M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+80.05 upside

Dividends

By Dow Jones

Next Earnings

31 Jul 2024

Market Stats

By TradingEconomics

Market Cap

301M

1.8B

Previous open

13.54

Previous close

6.96

News Sentiment

By Acuity

50%

50%

125 / 370 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Ardelyx Inc Chart

Related News

18 Oct 2023, 12:15 UTC

Major Market Movers

Ardelyx Shares Rally Premarket on FDA Approval of Xphozah

Peer Comparison

Price change

Ardelyx Inc Forecast

Price Target

By TipRanks

80.05% upside

12 Months Forecast

Average 14.08 USD  80.05%

High 15 USD

Low 12 USD

Based on 7 Wall Street analysts offering 12 month price targets forArdelyx Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

7

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

N/A / 7.69Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

125 / 370 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ardelyx Inc

Ardelyx, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines to improve treatment for people with kidney and cardiorenal diseases. The Company's product pipeline includes Tenapanor, IBSRELA, RDX013 Program, and RDX020 Program. The Tenapanor is a medicine for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor for the control of serum phosphorus has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). RDX013 Program is a small molecule potassium secretagogue program for the potential treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis. It has a discovery program targeting the inhibition of intestinal bicarbonate exchange for the treatment of metabolic acidosis.